Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Dr. Reddy's Laboratories Limited is a leading player in the global pharmaceutical market, focusing on generic and specialty drugs across various therapeutic areas. The company has a strong presence in India, the US, and Europe, with a diverse product portfolio that includes over 190 generic drugs and proprietary products, which provides a competitive edge in pricing and market access.
Dr. Reddy's generates revenue primarily through the sale of generic drugs, leveraging its extensive manufacturing capabilities and regulatory expertise to offer cost-effective alternatives to branded medications. The company benefits from strong pricing power in markets like the US, where patent expirations create opportunities for generic entry.
Approval of new generic drugs by the FDA, particularly in high-revenue therapeutic areas
Changes in healthcare regulations affecting pricing and reimbursement in key markets
Currency fluctuations, especially USD/INR, impacting revenue from exports
Market share gains in the US and Europe as competitors face supply chain issues
Regulatory changes that could impact drug pricing and market access
Technological disruption in drug development and manufacturing processes
Intensifying competition from both established players and new entrants in the generic market
Potential for increased pricing pressure in key markets
Low liquidity risk due to a strong current ratio, but reliance on cash flow for R&D funding
Potential currency risk from international sales impacting profitability
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but consumer spending on healthcare can be affected by broader economic conditions.
Higher interest rates could increase financing costs for R&D and capital expenditures, potentially impacting future growth and valuation multiples.
minimal - The company maintains a low debt-to-equity ratio, reducing its reliance on credit markets.
growth - Investors seeking exposure to the pharmaceutical sector with potential for high returns from generic drug approvals and market expansion.
moderate - The stock has shown some price fluctuations, but its fundamentals provide a degree of stability.